Q1 2026 CareDx Inc Earnings Call Transcript
Key Points
- CareDx Inc (CDNA) reported a 39% increase in total revenue for Q1 2026, reaching $118 million.
- Testing services revenue grew by 48% to $91 million, with a 17% increase in testing volume.
- The company announced the acquisition of Naveris, expanding its portfolio into the specialty oncology market.
- CareDx Inc (CDNA) raised its 2026 revenue guidance to $447 million to $465 million, indicating strong growth expectations.
- The divestiture of the Lab Products business will streamline operations and provide $170 million in upfront cash, enhancing financial flexibility.
- Lab products revenue declined by 4% to $10 million, indicating challenges in this segment.
- The company faces uncertainties related to the timing and impact of the LCD for transplant from the MolDx Group.
- Despite strong revenue growth, the underlying transplant procedure volumes remain sluggish.
- Naveris' GYN cancer indication is still in development, with no specific timeline for launch.
- The integration of Naveris may require significant operational adjustments, including potential changes to lab strategies.
Hello, everyone. Thank you for joining us, and welcome to CareDx Q1 2026 financial results earnings call. (Operator Instructions)
I will now hand the conference over to Caroline Corner, Investor Relations. Caroline, please go ahead.
Thank you, operator. Good afternoon. Thank you for joining us today. Earlier today, CareDx released financial results for the first quarter of 2026 ending March 31, 2026. The results are currently available on the company's website at www.caredx.com.
Joining me on today's call are John Hanna, President and Chief Executive Officer; Keith Kennedy, Chief Operating Officer and Chief Financial Officer; and Dr. Jeffrey Teuteberg, Chief Medical Officer.
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that are not statements of historical facts should be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
